A
Abhinav Sidana
Researcher at University of Cincinnati Academic Health Center
Publications - 99
Citations - 1249
Abhinav Sidana is an academic researcher from University of Cincinnati Academic Health Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 18, co-authored 90 publications receiving 966 citations. Previous affiliations of Abhinav Sidana include All India Institute of Medical Sciences & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Treatment decision‐making for localized prostate cancer: What younger men choose and why
Abhinav Sidana,David J. Hernandez,Zhaoyong Feng,Alan W. Partin,Bruce J. Trock,Surajit Saha,Jonathan I. Epstein +6 more
TL;DR: Insight into information sources consulted and factors dictating treatment decision‐making in young prostate cancer patients are provided.
Journal ArticleDOI
Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology—Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?
Brian P. Calio,Abhinav Sidana,Abhinav Sidana,Dordaneh Sugano,Sonia Gaur,Mahir Maruf,Amit Jain,Maria J. Merino,Peter L. Choyke,Bradford J. Wood,Peter A. Pinto,Baris Turkbey +11 more
TL;DR: It is demonstrated that saturation of the index lesion significantly decreases the risk of upgrading on radical prostatectomy by minimizing the impact of tumor heterogeneity.
Journal ArticleDOI
Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy
Akhil Muthigi,Arvin K. George,Abhinav Sidana,Michael Kongnyuy,Richard Simon,Vanessa Moreno,Maria J. Merino,Peter L. Choyke,Baris Turkbey,Bradford J. Wood,Peter A. Pinto +10 more
TL;DR: Magnetic resonance imaging and fusion biopsy rarely missed clinically significant prostate cancer as only 62 of 1,003 cases (6.2%) were upgraded to clinically significant disease by systematic biopsy.
Journal ArticleDOI
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
Amir H. Lebastchi,Arvin K. George,Thomas J. Polascik,Jonathan A. Coleman,Jean de la Rosette,Baris Turkbey,Bradford J. Wood,Michael A. Gorin,Abhinav Sidana,Sangeet Ghai,Kae Jack Tay,John F. Ward,Rafael Sanchez-Salas,Berrend G. Muller,Bernard Malavaud,Pierre Mozer,Sebastien Crouzet,Peter L. Choyke,Osamu Ukimura,Ardeshir R. Rastinehad,Peter A. Pinto +20 more
TL;DR: In this paper, the authors present expert opinion on the use of a standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer.
Journal ArticleDOI
Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.
Brian P. Calio,Abhinav Sidana,Dordaneh Sugano,Sonia Gaur,Amit Jain,Mahir Maruf,Sheng Xu,Pingkun Yan,Jochen Kruecker,Maria J. Merino,P. L. Choyke,Baris Turkbey,Bradford J. Wood,Peter A. Pinto +13 more
TL;DR: The results show that after an early learning period, Fbx detected higher rates of CS cancer and lower rates of clinically insignificant cancer than Sbx, and software advances allowed for even greater detection of CS disease.